Table 2.
Distribution of the most prevalent fusion transcript variants by exon usage in the current study
| Histotype | Fusion transcript variant | Number | Percentage |
|---|---|---|---|
| Angiomatoid fibrous histiocytoma (AFH) | EWSR1-ATF1 ex7-ex5 | 3 | 37.5 |
| EWSR1-ATF1 ex7-ex7 | 1 | 12.5 | |
| EWSR1-CREB1 ex7-ex7 | 3 | 37.5 | |
| Clear cell sarcoma (CCS) | EWSR1-ATF1 ex7-ex4 | 1 | 5.6 |
| EWSR1-ATF1 ex7-ex5 | 3 | 16.7 | |
| EWSR1-ATF1 ex8-ex4 | 10 | 55.6 | |
| EWSR1-ATF1 ex9-ex4 | 2 | 11.1 | |
| EWSR1-CREB1 ex7-ex7 | 1 | 5.6 | |
| EWSR1-CREM ex8-ex7 | 1 | 5.6 | |
| Clear cell sarcoma-like tumor of the gastrointestinal tract (GICCS) | EWSR1-ATF1 ex7-ex5 | 1 | 11.1 |
| EWSR1-ATF1 ex8-ex4 | 5 | 55.6 | |
| EWSR1-CREB1 ex6-ex6 | 1 | 11.1 | |
| EWSR1-CREB1 ex7-ex6 | 1 | 11.1 | |
| EWSR1-CREB1 ex7-ex7 | 1 | 11.1 | |
| Hyalinizing clear cell carcinoma (HCCC) | EWSR1-ATF1 ex7-ex4 | 1 | 14.3 |
| EWSR1-ATF1 ex8-ex4 | 1 | 14.3 | |
| EWSR1-ATF1 ex9-ex2 | 1 | 14.3 | |
| EWSR1-ATF1 ex10-ex3 | 1 | 14.3 | |
| EWSR1-ATF1 ex11-ex3 | 3 | 42.9 | |
| Malignant epithelioid neoplasm with predilection for mesothelial-lined cavities (ME) | FUS-CREM ex8-ex5 | 1 | 50.0 |
| FUS-CREM ex8-ex7 | 1 | 50.0 | |
| Mesothelioma (Meso) | EWSR1-ATF1 ex7-ex5 | 1 | 33.3 |
| EWSR1-ATF1 ex13-ex5 | 1 | 33.3 | |
| EWSR1-CREM ex10-ex5 | 1 | 33.3 |